MedPath

A prospective, randomised, phase IV, open label clinical trial to study the therapeutic use of buprenorphine 20 mg (BuTrans 20µg/h) matrix transdermal patch in the management of post tonsillectomy pain in adults - PATCH Trial

Phase 1
Conditions
post-tonsillectomy pain
Registration Number
EUCTR2007-006117-16-GB
Lead Sponsor
Betsi Cadwaladr University Health Board
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
Not specified
Target Recruitment
300
Inclusion Criteria

Patients undergoing tonsillectomy, which meet the following criteria:
•aged 18 to 50 years old;
•ASA grade I & II - healthy patient; mild systemic disease with no functional limitation (e.g. well controlled HTA)

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) no
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

•age less than 18 or over 50;
•ASA grade III - severe systemic disease with definite functional limitation e.g. unstable angina)
•conditions in which the respiratory centre and function are severely impaired or may become so;
•asthmatic and allergic to NSAIDS;
•hypotension
•pregnancy and lactation;
•recent head injury;
•known hypersensitivity towards the active substance buprenorphine or to any of the excipients (for the excipients see section 6.1);
•in opioid-dependent patients and for narcotic withdrawal treatment;
•patients who are receiving MAO inhibitors or have taken them within the last two weeks;
•patients suffering from myasthenia gravis;
•patients suffering from delirium tremens or acute alcohol intoxication;
•convulsive disorders

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath